Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases.
Leal Therapeutics develops novel therapeutics for patients.
Khartis is a drug discovery company developing oral therapies for immune-mediated and chronic diseases, with a focus on treatments and care.
Vedana Therapeutics is a Seattle biotechnology company developing next-generation antibody therapies for migraine prevention.
CREATE Medicines is a biotech company developing in vivo CAR therapies using mRNA-LNP immune cell programming technology.
Autoimmunity BioSolutions develops a future immuno-corrective treatment that restores healthy immune function.
Fathom Therapeutics focuses on drug design by harnessing biomolecular motion to develop therapeutics that can reprogram protein function.
Neomorph develops protein degradation therapies targeting diseases not addressed by conventional treatments.
Kytopen develops genome engineering platforms that enable cell therapy research and manufacturing.
Recludix pharma is a developing platform to treat cancer patients.
Eclipse Bioinnovations is an RNA genomics company that provides products and services to academic and industry customers around the world.
Accipiter Biosciences is a biotechnology company.
Tr1x is a biotechnology company developing novel cellular immunotherapies for patients with autoimmune and inflammatory diseases.
NILO Therapeutics is a biotechnology and therapeutics company.
AeroRx Therapeutics is a biopharmaceutical company that developing proprietary, combination products.
Thryv Therapeutics is a precision medicine approach to treat patients with Long QT Syndrome and potentially other arrhythmias.
Dualitas Therapeutics is leading the way in bispecific antibody treatments for inflammatory and immunological (I&I) disorders
Harpe Bio develops sustainable weed control solutions for organic and industrial agriculture.
Dispatch Biotherapeutics develops immunotherapy that treats solid tumors, which could significantly advance cancer treatment options.
GeneCentric Therapeutics develops and commercializes molecular diagnostic tests for oncologists and patients.
Remedy Plan is a pre-clinical cancer therapeutics company developing first-in-class small molecule drugs that differentiate cancer cells.
Hoofprint Biome is a biotechnology company that develops probiotics that improve the sustainability of ruminant livestock production.
March Biosciences is a clinical-stage cell therapy company that develops CAR-T cell strategies to address hematological cancers.
Garuda Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat severe and life-threatening diseases.
Alexandria Venture Investments has invested in 184 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Alexandria Venture Investments's top investment sectors include Biotechnology, Health Care, Therapeutics, Life Science, Medical. The firm invests across 20 different industry categories.
Among tracked funding rounds, Dispatch Bio received $216.0M in a Series A round. Alexandria Venture Investments's total known invested capital is $8.0B.
Alexandria Venture Investments's average investment size is $43.4M across its portfolio of 184 companies.
Recent Alexandria Venture Investments portfolio additions include Georgiamune, Leal Therapeutics, Khartis Therapeutics, Vedana Therapeutics, CREATE Medicines. These companies were founded in 2020 or later.